Premium
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non‐Hodgkin's lymphoma
Author(s) -
Hollister Dickerman,
Silver Richard T.,
Gordon Bruce,
Coleman Morton
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19821101)50:9<1690::aid-cncr2820500906>3.0.co;2-z
Subject(s) - medicine , vincristine , bleomycin , leukopenia , methotrexate , bolus (digestion) , pneumonitis , lymphoma , gastroenterology , prednisone , continuous infusion , anesthesia , chemotherapy , surgery , cyclophosphamide , lung
Sixteen patients with resistant non‐Hodgkin's lymphoma were treated with continuous infusions of vincristine (1–2 mg/m 2 daily X 2 days) and bleomycin (0.25 mg/kg bolus dose, then 0.25 mg/kg/daily X 5 days). Responding patients received high dose methotrexate (1500 mg/m 2 ) with citrovorum rescue on days 15, 22, 29, 36. Treatment cycles were repeated every six weeks in responding patients. The response frequency was 50% (three complete and five partial responses). Median response duration was 29 weeks. Major toxicity included stomatitis (63%) and leukopenia (44%). One episode each of possible hypersensitivity pneumonitis and paralytic ileus occurred. Continuous infusions of vincristine and bleomycin should be studied further in less critically ill patients.